The US Food and Drug Administration (FDA) has granted 510(k) clearance for Becton, Dickinson and Company’s (BD) Rotarex Atherectomy System expanded indications.

A rotational excisional device, the Rotarex Atherectomy System is designed to remove and aspirate varying lesion morphologies, including plaque and thrombus, in peripheral arteries.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It has already secured clearance for use in native arterial vessels.

Now, the device has expanded indications for treatments inside peripheral arteries that are fitted with stent grafts, stents, and native or artificial bypasses.

The Rotarex Atherectomy System has a small plug-and-play capital component and reusable handle, which makes it easy to use and simple to set up. It does not require infusions or catheter cleanout.

It is claimed to be the first and only atherectomy and thrombectomy device which is indicated to treat in-stent restenosis in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The FDA clearance of the device’s expanded indication for treatments within peripheral arteries comes after more than ten years of real-world clinical experience.

The clearance will allow physicians to use the Rotarex Atherectomy System to address some of their most challenging peripheral arterial disease (PAD) lesions.

BD peripheral intervention worldwide president Paddy O’Brien said: “The additional indications provide physicians a one-of-a-kind, ideal solution for treating complex lesions associated with PAD and further demonstrates our responsibility as an industry to develop innovative technologies to help with the fight against PAD.”

The device’s unique mechanism enables the simultaneous treatment of plaque and thrombus.

In June, the FDA expanded its 510(k) clearance for the BD PeritX Peritoneal Catheter System to drain symptomatic, recurrent, non-malignant ascites.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Awarded for Innovation in Remote Hearing Diagnostics , hearX’s Self Test Kit (STK) delivers clinically validated audiometry via smart devices, enabling remote, scalable hearing assessments in homes, clinics and retail. Learn how hearX is redefining hearing care delivery and reducing costs for providers globally.

Discover the Impact